SEC Form 4 · accession 0001457612-18-000101
GENOCEA BIOSCIENCES, INC. · GNCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Andrew Davis
Officer — CHIEF MEDICAL OFFICER
Period of report
Oct 1, 2018
Accepted (ET)
Oct 2, 2018 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001457612
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.79 | Oct 1, 2018 | A | 500,000 | A | — | Oct 1, 2028 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F11. The Stock Option shall become exercisable as to 25% of the maximum number of shares on October 1, 2019, and as to an additional 2.0833% of the total number of shares on each monthly anniversary thereafter